West Pharmaceutical reports Q3 adjusted EPS $1.85, consensus $1.50

Reports Q3 revenue $746.9M, consensus $709.62M. Eric M. Green, president, CEO and chair of the board commented; “We are pleased to report solid third quarter results. Our West team across the globe continues to execute at a high-level, motivated by our purpose of improving patient lives. A key aspect of our strategy is West’s team of scientific thought leaders and technical experts who continue to drive strong partnership and close collaboration with our customers. This reinforces my confidence in West’s execution capabilities, as we continue to deliver our proven market-led strategy and attractive long-term potential.”